Storyline
New therapeutic targets emerge for aggressive cancers with BRAF mutations and wild-type alleles
Coverage centers on: bioRxiv preprints on cancer signaling pathways.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- High resolution interaction surface mapping by PRISMA reveals novel ARID1A interactionsbioRxiv (all subjects)